Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2012

News provided by

Oct 24, 2011, 08:30 ET

SUNNYVALE, Calif., Oct. 24, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its first quarter of fiscal year 2012, ended September 30, 2011 on Tuesday, November 8, 2011 after the market closes.

A conference call to review the results of its first quarter of fiscal year 2012 will begin at 2:00 p.m. PST/5:00 p.m. EST and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer and Derek Bertocci, senior vice president and chief financial officer.

The conference call dial-in numbers are 1-800-789-2884 (USA) or +1-617-614-6207 (International), Conference ID: 13731949. In addition, a dial-up replay of the conference call will be available beginning November 8, 2011 at 5:00 p.m. PST/8:00 p.m. EST and ending on November 22, 2011. The replay telephone number is 1-888-286-8010 (USA) or +1-617-801-6888 (International), Conference ID: 47941705.

A live webcast of the call will also be available from the Investor Relations section of the corporate website at http://www.accuray.com/investors. A webcast replay can be accessed on the corporate website beginning Tuesday, November 8, 2011 at approximately 5:00 p.m. PST/8:00 p.m. EST. The replay will remain available until Accuray announces its results for the second quarter of fiscal 2012, ending December 31, 2011.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 582 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

SOURCE Accuray Incorporated